Research progress of high-dose cytarabine treating acute myeloid leukemia

At present, treatment of acute myeloid leukemia (AML) is mainly dependent on modifications of chemotherapy and hematopoietic stem cell transplantation (HSCT). Among them, high-dose cytarabine (HDAC) is an important choice for AML induction and consolidation therapy. Based on early findings of pivotal trial, many AML experts hold that HDAC for 4 consolidations is standard consolidation therapy. Recent evidence has provided new insights into the optimal dose, timing, course of HDAC, and the role of HDAC combination with other drugs in the treatment of AML. Therefore, HDAC is optimized. This article reviews literatures on HDAC for acute myeloid leukemia treatment. Key words: Leukemia, myeloid, acute; Cytarabine; Dose-response relationship, drug; Hematopoietic stem cell transplantation; Adult